^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CCR2 (C-C Motif Chemokine Receptor 2)

    i
    Other names: CCR2, C-C Motif Chemokine Receptor 2, CC-CKR-2, MCP-1-R, CMKBR2, CD192, CKR2, Monocyte Chemoattractant Protein 1 Receptor, Chemokine (C-C Motif) Receptor 2, C-C Chemokine Receptor Type 2, FLJ78302, CCR-2, Monocyte Chemotactic Protein 1 Receptor, MCP-1 Receptor, CD192 Antigen, C-C CKR-2, CCR2A, CCR2B, CKR2A, CKR2B
    1d
    Osteoprotegerin-Enabled Immune Evasion of Pathological Adipose Stromal Cells Drives Metabolic Dysfunction in Obesity. (PubMed, bioRxiv)
    Together, these findings identify sAPCs as a pathological stromal population that expands in obesity through elaboration of immunomodulatory factors. In particular, secreted OPG enables sAPCs to evade iNKT-mediated immune surveillance and contributes to metabolic dysfunction, highlighting OPG and sAPCs as promising therapeutic targets for restoring AT immune and metabolic homeostasis.
    Journal
    |
    CCR2 (C-C Motif Chemokine Receptor 2) • POSTN (Periostin) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B)
    2d
    Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation. (PubMed, JCI Insight)
    Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRAS-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in bAVM patients.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    KRAS mutation • KRAS G12
    |
    minocycline
    3d
    Macrophage-derived chemokines in T cell regulation: implications for cancer immunotherapy. (PubMed, Front Immunol)
    In contrast, M1-like macrophages could produce CXCL9 and CXCL10, activating effector CD8+ T cells, thereby enhancing anti-tumor immunity. Finally, the promising therapeutic potential of targeting specific chemokine signaling axes, such as CCL2/CCR2 and CXCL10/CXCR3, was discussed as a strategy to improve the efficacy of cancer immunotherapy.
    Review • Journal
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CCR2 (C-C Motif Chemokine Receptor 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    5d
    Convergent Multistage Evidence Implicates the CCR2-Artemin Immune-Inflammation Axis in Acute Myeloid Leukemia. (PubMed, Mediators Inflamm)
    Pathway analyses highlighted membrane-proximal processes (external plasma membrane and IgG binding) and a 16p11.2 signal. This integrative analysis identified CCR2-ARTN as a mechanistically supported immune-inflammation axis contributing to AML risk, offering a potential therapeutic target and warrants direct validation in primary CD62L + myeloid DCs.
    Journal • IO biomarker
    |
    CCR2 (C-C Motif Chemokine Receptor 2) • CD40LG (CD40 ligand) • IL33 (Interleukin 33) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2)
    8d
    High-dimensional phenotyping reveals novel macrophage-like and hybrid subsets within murine splenic conventional dendritic cells. (PubMed, PLoS One)
    This study employed multi-parametric flow cytometry and clodronate liposome (CL) depletion to systematically re-evaluate splenic CD11chighMHCIIhigh cDCs in C57BL/6 mice...These findings demonstrate unprecedented cDC plasticity driven by microenvironmental signals, revising conventional classification frameworks and proposing new targets for DC-based immunotherapies in autoimmunity and cancer. Our phenotypic mapping provides a foundational framework for future functional investigations into these novel subsets.
    Preclinical • Journal
    |
    MERTK (MER Proto-Oncogene, Tyrosine Kinase) • CD4 (CD4 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • CDK1 (Cyclin-dependent kinase 1) • ITGAX (Integrin Subunit Alpha X) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    clodronate disodium
    8d
    Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets. (PubMed, Curr Issues Mol Biol)
    Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type-specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers.
    Review • Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCR4 (C-C Motif Chemokine Receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL21 (C-C Motif Chemokine Ligand 21) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL27 (C-C Motif Chemokine Ligand 27) • CCR2 (C-C Motif Chemokine Receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CCR6 (C-C Motif Chemokine Receptor 6)
    |
    Poteligeo (mogamulizumab-kpkc)
    10d
    Depression-related chronic stress promotes ovarian cancer progression via metabolic dysfunction and IRF1-mediated immune suppression. (PubMed, Brain Behav Immun)
    These findings suggest that depression may be associated with ovarian cancer progression by remodeling the immune-metabolic microenvironment. This study highlights antidepressant therapy combined with anti-tumor treatment as a potential strategy for ovarian cancer patients with comorbid depression.
    Journal
    |
    IRF1 (Interferon Regulatory Factor 1) • CCR2 (C-C Motif Chemokine Receptor 2)
    12d
    Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population. (PubMed, Bladder Cancer)
    Prior studies have shown conflicting results regarding the association between bladder cancer risk and the CCL2 rs1024611 and CCR2 rs1799864 polymorphisms. We were unable to validate significant findings regarding any relationship between these polymorphism distributions across individuals with or without bladder cancer in a cohort of non-Hispanic White and Hispanic White men, suggesting no role of CCL2/CCR2 polymorphisms in bladder cancer.
    Journal
    |
    CCL2 (Chemokine (C-C motif) ligand 2) • CCR2 (C-C Motif Chemokine Receptor 2)
    16d
    Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. (PubMed, J Immunother Cancer)
    In 1L PDAC, BMS-813160 300 two times a day+gem/nabP±nivolumab demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clinical efficacy was not demonstrated.
    P1/2 data • Journal
    |
    CCR2 (C-C Motif Chemokine Receptor 2)
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium • BMS-813160
    17d
    Alterations of mucosal-associated invariant T cells in dermatomyositis. (PubMed, Clin Exp Rheumatol)
    The reduced frequency of MAIT cells in DM may be associated with excessive activation. The increased secretion of IFN-γ by MAIT cells may contribute to DM pathogenesis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    17d
    The CDK inhibitor Roscovitine enhances the therapeutic efficacy of anti-PD-1 in non-small cell lung cancer. (PubMed, Front Oncol)
    These findings demonstrate that Roscovitine potentiates anti-PD-1 therapy by simultaneously suppressing immunosuppressive cell populations and amplifying effector immune responses. The dual modulation of PD-L1 expression and immune cell dynamics provides a strong rationale for the clinical evaluation of Roscovitine in combination with immune checkpoint blockade in NSCLC and potentially other solid tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CCR2 (C-C Motif Chemokine Receptor 2)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    seliciclib (CYC202)
    27d
    Modulating NOS2 of radiotherapy-recruited CCR2+ macrophages enhances radiosensitivity of hepatocellular carcinoma. (PubMed, Radiother Oncol)
    CCR2+ myeloid cells suppress NOS2-mediated antitumor responses in HCC following RT. Targeting RT-recruited CCR2+ myeloid cells may offer a promising radiosensitizing strategy to overcome therapeutic resistance in HCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CCL2 (Chemokine (C-C motif) ligand 2) • CALR (Calreticulin) • CCR2 (C-C Motif Chemokine Receptor 2) • NOS2 (Nitric Oxide Synthase 2)